In spite of enormous efforts there have been no solutions to date for preventing/ terminating chronic disorders of humans by vaccination or drugs. Yet it is well understood that if the target antigen (ag) could be presented appropriately to the cells of the immune system then solutions could be found. Recently, the Barabas research group has introduced and described the third vaccination method – called modified vaccination technique (MVT) – which has the ability to provide a corrective immune response in experimental animals with an autoimmune kidney disease. Injections of immune complexes – made up of the target ag and specific non-pathogenic IgM antibodies directed against the target ag – achieved downregulation of pathogenic immune responses and tolerance to self was regained. Utilizing the immune system’s natural abilities to respond to corrective information, the MVT was able to prevent an autoimmune kidney disease from occurring (prophylactic effect) in experimental animals, and when present, terminating it (therapeutic effect) specifically and without measurable side effects.

It is predicted that the application of the MVT will have the potential in the future to revolutionize the preventative and therapeutic options for dealing with chronic disorders in humans (such as autoimmune disease, cancer and chronic infections) and achieve cures.

Barabas AZ, Cole CD, Lafreniere R, Weir DM (2015) Modified Vaccination Technique Designed to Prevent and Cure Chronic Disorders. Ann Vaccines Immunization 2(1): 1009.

aab: Autoantibody; aag: Autoantigen; ab: Antibody; ag: Antigen; BB: Brush Border; GBM: Glomerular Basement Membrane; HN: Heymann Nephritis; IC: Immune Complex; MGN: Membranous Glomerulonephritis; MVT: Modified Vaccination Technique; rKF3: Rat Kidney Fraction 3; rarKF3: Rat Anti-Rat Kidney Fraction 3; SPHN: Slowly Progressive Heymann Nephritis.

Vaccination to prevent infectious and contagious diseases to occur in humans was first employed by Edward Jenners in 1796 to protect against small pox. He used cow-pox derived vaccinia and scratched the viral fluid on the upper outer aspect of the arm. Being an antigenically similar but not a pathogenic disease causing virus in humans, it protected the vaccinated host by developing cross-reactive antibodies (abs). After small pox vaccine, several other vaccination programs were implemented, first by Pasteur and subsequently by others. In fact, prophylactic vaccination to protect humans from several infectious and contagious diseases to occur is successfully employed today. Prophylactic vaccination works by an active immunization program. Most often an attenuated or killed bacteria or virus is introduced into the vaccinated host with or without adjuvants. The individual’s immune system by responding to the injected material produces neutralizing and/or microbial killing abs which are able to eliminate the infectious agent.

The second form of vaccination is called passive immunization. It was introduced by von Behring in 1891 against diphtheria and tetanus. He produced anti-toxins in horses and rabbits against the two bacterial toxins. The injected ab in the infected host neutralized the tissue damaging toxins and the lives of most patients were spared. Since abs were produced in horses and rabbits they caused Arthus reactions, especially in tetanus treated patients, when injected with the product for the second or subsequent times. Since the employment of active immunization programs and antibiotics to protect or treat diphtheria, tetanus and numerous other bacterial and viral agent causing diseases, passive immunization is no longer widely utilized in medical practice. However, passive immunization started to be employed quite extensively in the last few years for different treatments. Recently, monoclonal abs are produced against cancer specific antigens (ags) and cell lines to treat patients with various forms of cancer and autoimmune diseases [1-7]. The treatment programs require the injection of humanized monoclonal abs to target cell surface receptors to reduce disease causing events.

Animal experiments in mice predisposed to breast cancer using prophylactic vaccination from eight weeks of age against Alpha-lactalbumin (a cancer specific target ag which is present abundantly on breast cancer cells) revealed that a protective pathogenic autoimmune response prevented the development of breast cancer [8-10].

While both forms of vaccinations (active and passive immunizations) have useful and beneficial properties they cannot successfully terminate autoimmune disorders such as autoimmune diseases and cancer. The reasons are many:

• In autoimmune disorders, quite often the etiology and pathogenesis of the disease are not known and equally how to remove the modified autoantigen (aag) from the system which maintains the disease.

• In cancer, it is often not known how to target cancer cells, with unique cancer specific antigenic surface markers, for elimination without causing collateral damage.

The Barabas research group realized and subsequently demonstrated that special immunological interventions were needed to deal with the modified endogenous ag initiated and maintained disorders. They developed the third vaccination program that is called modified vaccination technique (MVT) [11-14]. It promises to prevent the development of certain autoimmune disorders, and when present, terminate them specifically with minimal side effects, utilizing the immune system’s natural abilities to respond to corrective information present in the inoculum.

Presently available vaccination techniques are unable to prevent or treat chronic ailments such as cancer, autoimmune diseases and chronic infections. Yet it is known for certainty that the presentation of ags to the cells of the immune system, whether exogenous or endogenous in nature, determine the immune response outcome. The same exogenous or endogenous ag that can cause disease – in our opinion and experience – can also provide cure if it is presented to the cells of the immune system in a suitable form.

While most exogenous infectious agents such as tetanus, measles, whooping cough, smallpox etc. are well represented in vaccines to evoke protective immune responses in immunized hosts, endogenous ags are not, whether present in natural forms or in purified extracts [15,16]. Induction of prophylactic and therapeutic responses to correct/terminate autoimmune diseases and cancer are complex. The purpose of this scientific paper is to describe and highlight those corrective immune responses which we have developed and could achieve – with minimal side effects – regained health. While certain environmental agents can cause or contribute to the development of the above disorders [17-26] we are mainly interested in those immunological processes which allow regained tolerance to self; tolerance to those intact healthy cells which serve special functions.

Chronic disorders caused by outside (bacteria, virus) [14] and inside agents (such as chemicals, toxins etc. making self to modified self ags) [25,27] cannot presently be prevented or treated by available medical interventions specifically without causing side effects. We still rely on experiments carried out in mice, rats etc. to study the etiology, pathogenesis [27,28] and possible treatment options [29] of chronic ailments using drugs, monoclonal abs [4,30-33], radiation, surgery etc. Yet in most instances corrective immune mediated responses – would we know how to implement them – could result in recovery [34]. Since we have worked with Heymann nephritis (HN) [35-37] and slowly progressive Heymann nephritis (SPHN) [27,38] for years, we shall illustrate and describe the various immune events in normal and in SPHN rats and how to reinstate normal health by terminating pathogenic autoimmune disease causing events [12,29].

SPHN in Wistar rats was induced by injections of chemically modified rat kidney tubular extracts in Alum [38]. Animals developed the autoimmune kidney disease slower than those which were injected with the same tubular fraction in Freund’s complete adjuvant [35]. The disease was characterized by the presence of circulating pathogenic IgG autoantibodies (aabs) [36], directed against the nephritogenic ag, causing primary injury to the renal proximal convoluted tubular brush border (BB) [38] and secondary injury to the glomeruli by depositing immune complexes (ICs) [38]. The two renal injuries to the proximal renal tubular BB and the glomeruli took the following course:

• The pathogenic IgG aab, directed against the renal tubular fraction injected ag, targeted the nephritogenic ag which is abundantly present in the BB region of the renal tubules. Indirect fluorescence ab tests (using dilutions of sera on normal rat kidney sections and fluorescent labelled anti-rat IgG ab) convincingly demonstrated the intensity of the attack of the circulating ab against the renal tubules [38].

• For years it was not understood, and in the meantime was controversial, why massive deposition of ICs – made up of the nephritogenic ag and pathogenic IgG aabs directed against it – settled on the epithelial side of the glomerular basement membrane (GBM) in HN, causing membranous glomerulonephritis (MGN). It has recently been shown by Barabas and colleagues that HN susceptible strains of rats [39] have tiny depositions of ICs around their glomeruli, made up of the nephritogenic ag and non-pathogenic IgM aabs directed against them [28]. More massive deposition of the same IC can be observed in the mesangium [28]. The fact is that these rats have minimal yet significant amounts of tubular nephritogenic ag in the glomeruli. When pathogenic IgG aabs are produced, following injections of the chemically modified nephritogenic ag in Alum, they not only target the BB region of the renal proximal convoluted tubules but the glomerular localized nephritogenic ag as well; and start an ag:ab reaction on the epithelial side of the GBM leading to chronic progressive deposition of ICs in the presence of complement [38,40].

The source of the nephritogenic ag in the circulation and in the glomeruli is from the pathogenic IgG ab damaged BB region of the proximal convoluted renal tubules.

The fate of the released nephritogenic ag from the kidneys of normal and SPHN rats into the circulation is as follows:

•  Most nephritogenic ag released into the circulation is removed by cross-reactive non-pathogenic IgM aabs [41- 44]. ICs formed by [nephritogenic ag X non-pathogenic IgM aabs directed against the nephritogenic ag] are degraded into small molecular weight re-utilizable peptides by mononuclear cells [45-47] (Figure 1).
• Some of the nephritogenic ags will stimulate the production of specific IgM aabs. These IgM aabs being cross-reactive are protective by nature and slow down pathogenic immune events by removing both modified and released native nephritogenic ags from the circulation thereby preventing/diminishing pathogenic IgG aab production and deposition of ICs (nephritogenic ag X pathogenic IgG aabs directed against the nephritogenic ag in the presence of complement) in the glomeruli.
• Some of the released nephritogenic ag will contribute to continuous formation of ICs in the glomeruli made up of layered deposition of nephritogenic ag, IgG aabs directed against the nephritogenic ag in the presence of complement (C-3, C5b-9) [40] (Figure 2).
• For immunopathological events to continue, the presence of modified nephritogenic ag, the ‘modified self,’ to produce pathogenic IgG aabs is an essential requirement [27].

• In the absence of native and modified nephritogenic ags in the circulation pathogenic IgG aab production declines and eventually ceases [48].                                                                               

  Fate of the modified nephritogenic ag is as follows:

• The administered modified nephritogenic ag, being foreign like, will initiate and if it is continuously present in the circulation will maintain the production of cross-reactive pathogenic IgG aabs directed against the modified aag which is present in the circulation and the nephritogenic ag which is present in the BB region of the renal proximal convoluted tubules. Having direct access to the native ag, the pathogenic IgG aab will cause morphological and functional changes, e.g., in HN and SPHN, in the BB region of the renal proximal convoluted tubules (the site where nephritogenic ag is present) and in the glomeruli, where IC depositions cause proteinuria [38] [Figure 3].
• There are specific non-pathogenic IgM aabs in the circulation throughout life directed against subcellular components [49]. When cells come to the end of their life span or damaged by various outside agents (such as toxins, drugs, chemicals, infectious agents, adjuvants etc.) [17,21,27,50-54] and released into the circulation some may become modified. If the modified aag represents a relatively small amount of cellular breakdown products, then specific cross-reactive nonpathogenic IgM aabs will assist their removal, thereby preventing toxic accumulation of degraded protein and possible production of pathogenic IgG aabs. However, if the modified aag is continuously available in the system (due to modifying agents being present) then developing pathogenic cross-reactive IgG aabs could start and maintain the autoimmune disease.
• Efficient removal of both modified and native damaged and released subcellular components from the circulation by specific non-pathogenic IgM aabs and mononuclear cells could prevent the occurrence of autoimmune diseases [55-57].

Autoantigenic components and aabs playing roles in the autoimmune disease SPHN

There are two aags and two aabs present in the system during SPHN [38]. Native and modified nephritogenic aags, and specific cross-reactive IgM aabs directed against native and modified nephritogenic ags and specific cross-reactive IgG aabs directed against native and modified nephritogenic ags.

One of the aags is the native nephritogenic ag which is frequently released from the BB cells of the renal proximal convoluted tubules into the circulation and urine. This aag is responsible for the continuous production of non-pathogenic cross-reactive IgM aabs against the nephritogenic ag during health and also during disease [38]. However, a portion of the native aag in the form of ICs [native nephritogenic aag X rat antirat nephritogenic aag IgG aab] and [native nephritogenic aag X rat anti-rat modified nephritogenic aag IgG aab] can also produce pathogenic IgG aabs during the course of the autoimmune disease [40].

The other aag is the modified nephritogenic ag which is derived from the renal proximal convoluted tubules after being released into the circulation and modified. This ag is responsible for the production of cross-reactive pathogenic IgG aabs directed against the BB zone of cells of the renal convoluted tubules; and it is also directed against the chemically or adjuvant modified nephritogenic ag [27,51]. During SPHN both aags are targeted by the developing cross-reactive pathogenic IgG aabs contributing to renal proximal convoluted tubular and glomerular injuries and to further production of pathogenic aabs by ICs made up of the [modified nephritogenic ag X rat anti-rat modified nephritogenic ag IgG aab]. Immunopathological events will continue as long as the modified nephritogenic ag is present in the system and capable of producing pathogenic IgG aabs [40,58]. As mentioned:

• The cross-reactive pathogenic IgG aab contributes to autoimmune disease development and progression [58]; while the other.
• Cross-reactive specific non-pathogenic IgM aab – directed against the nephritogenic ag – is responsible for the removal of both modified and native nephritogenic ags from the system [11,48,58]; and if the modified nephritogenic ag is diminished or becomes absent in the circulation, terminating autoimmune disease causing immunological processes, leading to full recovery.

Nephritogenic aags, and aabs against the nephritogenic ag, in normal healthy, and in regained tolerance to self rats’ circulation

During healthy state, only normal cellular breakdown products are present in the circulation; e.g., cell debris from the BB region of the renal proximal convoluted tubules derived from end of life span cells. These released aags initiate and maintain throughout life continuous production of specific non-pathogenic IgM aabs which assist in the removal of cellular breakdown products [41,43,46,59]. In a physiological sense there is no tolerance to inside cell located cellular components of normally functioning cells [43,44] and when cellular components are released from damaged or end of life span cells they are removed to prevent their toxic accumulation or possible modifications.

SPHN rats with regained tolerance to self from a modified nephritogenic ag caused autoimmune disease – after treatment with the MVT – have native nephritogenic ag and specific nonpathogenic IgM aabs in their circulation; the latter directed against the nephritogenic ag [60,61] just as it occurs in normal rats [11].

Lesions observed in the tubules and glomeruli of SPHN rats

The developing pathogenic IgG aabs, following injections of the modified nephritogenic ag, are directed against the injected renal tubular BB associated nephritogenic ag; and thereafter target the renal proximal convoluted tubule’s BB zone of cells [40,62] (primary damage to the kidney) and by damaging them release into the circulation and urine intracytoplasmic components including the nephritogenic ag. Severe injury to the tubules and glomeruli results in compromised re-absorption of glomerular filtrate, including proteins by the renal proximal convoluted tubules. The most obvious lesion is found in the glomeruli (secondary damage to the kidney) where layered deposition of nephritogenic ag and pathogenic IgG aabs directed against the nephritogenic ag in the presence of complement (C3, C5b-9) are observed on the epithelial side of the GBM. In the process of IC formation – resulting in osmiophilic deposits, as observed by electronmicroscopy – foot processes are fused and deposits are surrounded partially or completely by basement membrane material [40,63]. Changes in the GBM and epithelial cells lead to non-selective proteinuria through the irregularly thickened GBM.

The third vaccination technique for the prevention and when present termination of an experimental autoimmune kidney disease SPHN

The third vaccination method (i.e., MVT) can produce powerful predetermined immune response outcomes against both exogenous [64,65] and endogenous ags [11-13,29,48,58,66- 69] without the use of adjuvants. We describe its applicability in an autoimmune kidney disease below.

In a significant way specific IgM aabs [41,43,46] – which are present in the system throughout life [43,44,70] directed against intracytoplasmic components – together with mononuclear cells [42,71] are responsible for the maintenance of tolerance to self [47]. When cells break down due to outside influences or when reaching the end of their life span, they release intracytoplasmic ags into the circulation and are removed by specific nonpathogenic IgM aabs and digested into reusable peptides by mononuclear cells [45,46]. The specific non-pathogenic IgM aabs are cross-reactive [42,43]; they are able to remove native aags from the system thereby preventing toxic accumulation of cellular breakdown products or their modifications. They are also able to remove modified (chemically or otherwise) aags as well, thereby preventing the development of autoimmune diseases.

Barabas and colleagues have demonstrated:

• that increased IgM aab titres can be obtained in normal rats’ sera, against the renal cortical ag rich nephritogenic ag, following injections of native rat kidney fraction 3 (rKF3) ag in an aqueous solution [48];
• that by ab information transfer, employing donor rats’ derived rat anti-rat kidney fraction 3 (rarKF3) IgM ab and native rKF3 ag (rich in nephritogenic ag) in the form of IC [rKF3 ag X rarKF3 IgM ab] increased levels of specific IgM aabs, directed against the nephritogenic ag, can be obtained after injecting normal recipient rats with the IC [48];
• that injection of ICs composed of [rKF3 ag X rarKF3 IgM ab] at slight ag excess can result in increased IgM aab production against the nephritogenic ag in treated rats, allowing efficient removal of nephritogenic ags (both native and modified) from the system, thereby halting the production of renal tubular and glomerular injury causing pathogenic IgG aabs. This form of vaccination prevented the development of SPHN in rats injected with the nephritogenic ag in an adjuvant; and in rats with the chronic form of SPHN terminated immunopathological processes that would have otherwise maintained the autoimmune kidney disease [48] (Table 1).
• That the vaccination method we are describing is the third way of immunizing after active and passive immunizations. It is called MVT because every time we want to immunize there is a need for producing specific ags to be targeted and specific abs against the target ags. ICs made up of the native target ag and the physiologic IgM ab against the target ag will produce in the vaccinated host the same ab with the same specificity against the target ag as present in the inoculum [12-14,72]. The immunization method is specific and safe, imitating natural immune responses to occur in the vaccinated host to correct the inability or compromised ability of the immune system to produce powerful corrective therapeutic response(s).

Table 1: Downregulation/termination of an experimental autoimmune kidney disease – SPHN – by the implementation of the MVT

Barabas and colleagues have introduced the third vaccination technique – after active and passive immunizations – for the prevention and when present termination of certain exogenous and endogenous ag induced diseases [12-14,29,48,58,66,67]. The vaccine is introduced in an ab predetermined response format. The corrective immune responses are evoked by the immune system’s natural abilities to initiate, and following continuous immunization, maintain the appropriate response, i.e., producing the same ab with the same specificity against the target ag that is present in the inoculum [12-14,72]. So far endogenous ag caused disorders such as autoimmune diseases and cancer have not been treated specifically to achieve cure. Medical interventions up until now have been used to achieve non-specific suppression of the immune system or the rapidly dividing cancer cells, thereby somewhat interfering with disease progression [4,30-34,73].

Prevention, progression and treatment of any disease depend upon the presentation of the disease causing ag to the cells of the immune system, whether it is exogenous or endogenous in nature. We have observed in an experimental autoimmune disease – SPHN – that the immune system is continually bombarded by released nephritogenic ags from the renal proximal convoluted tubules’ BB zone of cells and as a result specific IgM aabs are produced against them [38,40,74]. The role of the specific IgM aabs is to assist in the removal of the released nephritogenic ag from the system, thereby preventing its toxic accumulation and possible chemical alteration which could, if allowed to stay in the system long enough, cause an autoimmune disease. The released aags, after being removed by the specific IgM aabs, are digested into small molecular weight reusable peptides by mononuclear cells [45,46,75].

We have shown that in order for an experimental autoimmune disease called HN or SPHN to occur, the native ag, i.e., the nephritogenic ag, has to be modified chemically or otherwise; because only the modified aag can induce the production of pathogenic autoimmune disease causing IgG aabs in genetically susceptible strain of rats [39]. Once such aabs [27,38,76,77] are produced, the target ag in the BB region of the proximal convoluted tubules is damaged causing the autoimmune disease (primary injury by the pathogenic IgG aab) with consequent release of the nephritogenic ag into the circulation and urine. The released aag, by contributing to IC deposition in the glomeruli, together with pathogenic IgG aabs directed against the nephritogenic ag in the presence of complement, caused MGN (secondary injury by the pathogenic IgG aab) [40] [exacerbation]. In the meantime, the released nephritogenic ag contributed to the production of elevated IgM aabs which in turn, by removing both modified and native nephritogenic ags from the system, downregulated/ terminated the autoimmune disease causing immunopathological processes [27,38,40,48] [remission]. Without this inbuilt protective immune response most autoimmune diseases would progress rapidly damaging the target ag, causing functional and morphological injury in an organ.

During the chronic phase of the autoimmune disease it was observed that both pathogenic IgG and non-pathogenic IgM aabs were present in the circulation, directed against the nephritogenic ag [40]. The former maintained progression [exacerbation] and the latter aimed to downregulate/terminate the disease [remission]. Would we be able to initiate an increased non-pathogenic IgM aab response in SPHN rats against the native target ag (i.e., renal proximal convoluted tubules’ nephritogenic ag), then we would be able to:

• remove both released native and modified native nephritogenic ags from the circulation; and thereby

• prevent further production of disease maintaining/ progression causing pathogenic IgG aabs; and would

• regain tolerance to self;

Barabas and colleagues have worked out a new vaccination method which allows prophylactic and therapeutic interventions in rats with SPHN [11,48]. The vaccination technique is based on previous works showing that ICs used for immunization can enhance antibody response [78-84]. The third way of vaccination – after active and passive immunizations – is called MVT. It is eminently suitable to prevent and when present cure a pathogenic IgG aab induced and maintained experimental autoimmune kidney disease specifically, without noticeable side effects [11,48]. The vaccination is based on ab information transfer by administered ICs which are made up of the native target ag and non-pathogenic IgM ab directed against the native target ag. Vaccinating SPHN rats, ICs were made up of: [rKF3 ag X rarKF3 IgM ab] at ag excess. When the IC was injected into rats prior to the induction of SPHN, the level of circulating IgM aabs increased in the circulation and assisted in the elimination of both the modified and native nephritogenic ags and thus prevented the development of the kidney disease [11,48]. Animals injected with the same IC during the progressive phase of the kidney disease responded similarly with elevated specific IgM aab responses, which in turn, by removing the disease causing and contributing nephritogenic ags from the circulation, terminated the kidney disease [11,48].

Future possibilities for the employment of the MVT in humans are encouraging for preventing and when present terminating chronic disorders such as autoimmune diseases and cancer, specifically with minimal side effects.

1. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014; 16: 209.

2. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER2/neu as a target for cancer vaccines. Immunotherapy. 2010; 2: 213- 226.

3. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusionrelated side effects and rapid blood tumor clearance. J Clin Oncol. 1999; 17: 791-795.

4. Dörner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009; 5: 433-441.

5. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005; 4: 526-531.

6. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008; 99: 1415-1425.

7. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010; 237: 264-283.

8. Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med. 2010; 16: 799-803.

9. Kesaraju P, Jaini R, Johnson JM, Altuntas CZ, Gruden JJ, Sakalar C, et al. Experimental autoimmune breast failure: a model for lactation insufficiency, postnatal nutritional deprivation, and prophylactic breast cancer vaccination. Am J Pathol. 2012; 181: 775-784.

10. Tuohy VK, Jaini R. Prophylactic cancer vaccination by targeting functional non-self. Ann Med. 2011; 43: 356-365.

11. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int. 2006; 56: 181-190.

12. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics. 2007; 1: 59-68.

13. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann N Y Acad Sci. 2007; 1110: 619-629.

14. Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. A vaccination technique to combat presently untreatable chronic ailments. BioProcessing Journal. 2007; 6: 12-18.

15. Schulze C, Munoz LE, Franz S, Sarter K, Chaurio RA, Gaipl US. Clearance deficiency--a potential link between infections and autoimmunity. Autoimmun Rev. 2008; 8: 5-8.

16. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest. 2001; 108: 1097-1104.

17. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009; 5: 648-652.

18. Alballa S, Fritzler M, Davis P. A case of drug induced lupus due to carbamazepine. J Rheumatol. 1987; 14: 599-600.

19. Ghaussy NO, Sibbitt WL Jr, Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a casecontrol study. J Rheumatol. 2001; 28: 2449-2453.

20. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science. 1994; 266: 810-813.

21. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity. 2005; 38: 235-245.

22. Orbach H, Shoenfeld Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev. 2007; 6: 261-266.

23. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008. Isr Med Assoc J. 2008; 10: 8-12.

24. Totoritis MC, Rubin RL. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad Med. 1985; 78: 149-152, 155-61.

25. Weir DM. Altered antigens and autoimmunity. Vox Sang. 1969; 16: 304-313.

26. Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest. 1995; 73: 746-759.

27. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol. 2004; 85: 277-285.

28. Barabas AZ, Cole CD, Barabas AD, Cowan JM, Yoon CS, Waisman DM. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol. 2004; 85: 201-212.

29. Barabas AZ, Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev. 2005; 4: 565-570.

30. Blank M, Shoenfeld Y. B cell targeted therapy in autoimmunity. J Autoimmun. 2007; 28: 62-68.

31. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995; 25: 862-875.

32. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002; 46: 2673-2677.

33. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004; 44: 385- 401.

34. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature. 2005; 435: 612-619.

35. Barabas AZ, Lannigan R. Auto-immune nephritis in rats. J Pathol. 1969; 97: 537-543.

36. Barabas AZ, Elson CJ, Weir DM. The serology of autologous immune complex nephritis in the rat. Clin Exp Immunol. 1969; 4: 345-351.

37. Barabas AZ, Biggart JD, Lannigan R. The induction of autologous immune-complex nephritis in neonatally thymectomised rats. J Pathol. 1970; 101: 157-162.

38. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol. 2003; 84: 245-258.

39. Salant DJ, Cybulsky AV. Experimental glomerulonephritis. Methods Enzymol. 1988; 162: 421-461.

40. Barabas AZ, Cole CD, Lafreniere R, Weir DM. Implicated autoantibodies in a kidney disease. In Autoantibodies: detection, pathogenicity and health implications. Jenkins GE, Hall JI, editors. Hauppauge NY: Nova Science Publishers, Inc. 2012; 1-36.

41. Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol. 2005; 26: 425-432.

42. Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrowderived macrophages in vitro. Eur J Immunol. 2005; 35: 252-260.

43. Weir DM, Pinckard RN, Elson CJ, Suckling DE. Naturally occurring antitissue antibodies in rat sera. Clin Exp Immunol. 1966; 1: 433-442.

44. Weir DM, Pinckard RN. Failure to induce tolerance to rat tissue antigens. Immunology. 1967; 13: 373-380.

45. Batsford SR, Weghaupt R, Takamiya H, Vogt A. Studies on the mesangial handling of protein antigens: influence of size, charge and biologic activity. Nephron. 1985; 41: 146-151.

46. Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 2005; 38: 259-264.

47. Wermeling F, Karlsson MC, McGaha TL. An anatomical view on macrophages in tolerance. Autoimmun Rev. 2009; 9: 49-52.

48. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol. 2004; 85: 321-334.

49. Schoenfeld LS, Glassock RJ. Renal tubular antigen excretion in normal human urine. I. Immunochemical indentification. Kidney Int. 1973; 3: 309-314.

50. Favoino E, Favia EI, Digiglio L, Racanelli V, Shoenfeld Y, Perosa F. Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice. Clin Exp Immunol. 2014; 175: 32-40.

51. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL. Production of nephrotic syndrome in rats by Freund’s adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med. 1959; 100: 660-664.

52. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009; 18: 1217-1225.

53. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity--friends or foes? Trends Immunol. 2009; 30: 409-414.

54. Naito T, Kawamura T, Bannai M, Kosaka T, Kameyama H, Shimamura K. Simultaneous activation of natural killer T cells and autoantibody production in mice injected with denatured syngeneic liver tissue. Clin Exp Immunol. 2002; 129: 397-404.

55. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A. 2000; 97: 1184-1189.

56. Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med. 2000; 191: 1253-1258.

57. Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity. 2004; 37: 95-102.

58. Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scand J Immunol. 2010; 71: 125-133.

59. Weir DM. The immune response after tissue injury. Pathol Eur. 1966; 1: 108-118.

60. Singh AK, Makker SP. Circulatory antigens of Heymann nephritis. I. Identification and partial characterization. Immunology. 1986; 57: 467-472.

61. Singh AK, Schwartz MM. Circulatory antigen of Heymann nephritis. II. Isolation of a 70,000 MW antigen from normal rat serum which cross-reacts with Heymann nephritis antigen. Immunology. 1986; 59: 451- 458.

62. Barabas AZ, Cole CD, Lafreniere R, Weir DM. Regaining tolerance to a self-antigen by the modified vaccination technique. Clin Rev Allergy Immunol. 2013; 45: 193-201.

63. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010; 56: 157-167.

64. Barabas AZ, Cole CD, Kovacs ZB, Lafreniere R. Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit. 2007; 13: BR119-124.

65. Barabas AZ, Cole CD, Sensen M, Lafreniere R. Production of heterologous IgG antibody against Heymann nephritis antigen by injections of immune complexes. Int J Exp Pathol. 2012; 93: 11-17.

66. Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol. 2006; 13: 17-24.

67. Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun Rev. 2009; 8: 552-557.

68. Barabas AZ, Cole CD, Barabas AD, Lafreniere R, Weir DM. Four aspects of autoimmunity and how to regain tolerance to self from an autoimmune disease utilizing the modified vaccination technique. In Autoimmune disorders - current concepts and advances from bedside to mechanistic insights. Huang FP, editor. Rijeka, Croatia: InTech; 2011: 569-590.

69. Barabas AZ, Cole CD, Lafreniere R, Weir DM. A new vaccination method for exogenous and endogenous antigen initiated disorders. In Vaccinations: Procedures, Types and Controversy. Bezio AI, Campbell BE, editors. Hauppauge NY: Nova Science Publishers, Inc. 2012; 75-98.

70. Weir DM, Elson CJ. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum. 1969; 12: 254-260.

71. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complementdependent clearance of apoptotic cells by human macrophages. J Exp Med. 1998; 188: 2313-2320.

72. Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. New vaccination technology for endogenous antigen-derived ailments. IDrugs. 2008; 11: 111-115.

73. Lollini PL, Forni G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother. 2002; 51: 409-416.

74. Avrameas S. Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today. 1991; 12: 154-159.

75. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Pathogenic and nonpathogenic autoimmune events – the good and/or the bad? In Autoantibodies research progress. Dubois Q, editor. Hauppauge NY: Nova Science Publishers, In; 2008; 9-18.

76. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A. 1982; 79: 5557-5561.

77. Noble B, Van Liew JB, Andres GA, Brentjens JR. Factors influencing susceptibility of LEW rats to Heymann nephritis. Clin Immunol Immunopathol. 1984; 30: 241-254.

78. Haddad EE, Whitfill CE, Avakian AP, Ricks CA, Andrews PD, Thoma JA. Efficacy of a novel infectious bursal disease virus immune complex vaccine in broiler chickens. Avian Dis. 1997; 41: 882-889.

79. Jeurissen SH, Janse EM, Lehrbach PR, Haddad EE, Avakian A, Whitfill CE. The working mechanism of an immune complex vaccine that protects chickens against infectious bursal disease. Immunology. 1998; 95: 494-500.

80. Kunkl A, Klaus GG. The generation of memory cells. IV. Immunization with antigen-antibody complexes accelerates the development of B-memory cells, the formation of germinal centres and the maturation of antibody affinity in the secondary response. Immunology. 1981; 43: 371-378.

81. Terres G, Wolins W. Enhanced immunological sensitization of mice by the simultaneous injection of antigen and specific antiserum. I. Effect of varying the amount of antigen used relative to the antiserum. J Immunol. 1961; 86: 361-368.

82. Terres G, Stoner RD. Specificity of enhanced immunological sensitization of mice following injections of antigens and specific antisera. Proc Soc Exp Biol Med. 1962; 109: 88-91.

83. Wen YM. Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin Biol Ther. 2009; 9: 285-291.

84. Whitfill CE, Haddad EE, Ricks CA, Skeeles JK, Newberry LA, Beasley JN. Determination of optimum formulation of a novel infectious bursal disease virus (IBDV) vaccine constructed by mixing bursal disease antibody with IBDV. Avian Dis. 1995; 39: 687-699.